In this study, there is no correlation between the risk of recurrent stroke and the size of a PFO, the magnitude of the right-to-left shunt, or the presence of an atrial septal aneurysm.
This is an open label extension of 306 subjects from a previously reported delayed-start phase III clinical trial of rasagiline in early Parkinson's disease. Clinical benefit observed at one year in the early vs. delayed-start arm was maintained over an average 3.6 ± 2.1 years observation, raising the question of whether earlier intervention with rasagiline results in better outcomes.
Pathological gambling related to dopamine replacement therapy in Parkinson's disease is associated with overactivity of a right hemisphere network that includes regions involved in impulse control, reward, motivation, and memory.
